MedTrace Logo

Incretin Hormone Antagonism After Bariatric Surgery

NCT03950245 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2022-02-01

No results posted yet for this study

Summary

Using the glucagon-like peptide-1 (GLP-1) antagonist exendin(9-39) and the glucose-dependent insulinotropic peptide (GIP) antagonist GIP(3-30), the purpose of this study is to clarify the importance of endogenous GLP-1 and GIP for postprandial glucose metabolism after RYGB and SG in subjects with normal glucose tolerance. We hypothesize that GLP-1 is more important after RYGB, and GIP is more important after SG, for postprandial glucose tolerance and beta-cell function. A group of un-operated subjects with normal glucose tolerance will serve as controls.

Conditions

  • Bariatric Surgery

Interventions

OTHER

Placebo

Four-hour liquid mixed meal tests and a subsequent ad libitum meal during saline infusion.

OTHER

GLP-1 antagonism

Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin 9-39 and saline infusion.

OTHER

GIP antagonism

Four-hour liquid mixed meal tests and a subsequent ad libitum meal during GIP(3-30) and saline infusion.

OTHER

GLP-1 and GIP antagonism

Four-hour liquid mixed meal tests and a subsequent ad libitum meal during exendin and GIP(3-30) infusion.

Sponsors & Collaborators

  • Hvidovre University Hospital

    lead OTHER

Principal Investigators

  • Kirstine N Bojsen-Møller, MD, PHD · Dept. of Endocrinology, Hvidovre Hospital, Denmark

  • Morten G Hindsø, MD · Dept. of Endocrinology, Hvidovre Hospital, Denmark

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-01
Primary Completion
2021-04-16
Completion
2021-04-16

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03950245 on ClinicalTrials.gov